US 11,986,317 B1
Device and method for monitoring and assessment of movement disorder symptoms
Dustin A. Heldman, Shaker Heights, OH (US); Joseph P. Giuffrida, Hinckley, OH (US); and Thomas O. Mera, Columbus, OH (US)
Assigned to Great Lakes Neuro Technologies Inc., Cleveland, OH (US)
Filed by Great Lakes NeuroTechnologies Inc., Cleveland, OH (US)
Filed on Mar. 22, 2022, as Appl. No. 17/700,569.
Application 17/700,569 is a continuation of application No. 16/882,894, filed on May 26, 2020, granted, now 11,311,235.
Application 16/882,894 is a continuation of application No. 16/108,746, filed on Aug. 22, 2018, granted, now 10,694,992, issued on Jun. 30, 2020.
Application 16/108,746 is a continuation of application No. 15/210,990, filed on Jul. 15, 2016, granted, now 10,085,689, issued on Oct. 2, 2018.
Application 15/210,990 is a continuation of application No. 12/818,819, filed on Jun. 18, 2010, abandoned.
Int. Cl. A61B 5/00 (2006.01); A61B 5/11 (2006.01)
CPC A61B 5/4848 (2013.01) [A61B 5/0022 (2013.01); A61B 5/0077 (2013.01); A61B 5/1101 (2013.01); A61B 5/4082 (2013.01); A61B 5/6826 (2013.01); A61B 5/7405 (2013.01); A61B 5/742 (2013.01); A61B 2562/0219 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A therapy device combination for providing and/or adjusting therapy or treatment for a subject's movement disorder symptoms, the system comprising:
a) a drug dose adapted to be provided to the subject, or a drug pump or deep brain stimulation (DBS) device comprising therapy or treatment parameters, the drug pump or DBS device adapted to provide a drug dose or DBS therapy to the subject based on the therapy or treatment parameters;
b) a movement disorder monitoring device comprising a memory and at least one sensor adapted for acquiring movement data corresponding to movement disorder symptoms of at least one of the subject's extremities and to be in wired or wireless communication with at least one first processor, the at least one first processor being adapted to process and analyze the movement data and further to quantify severity of the subject's movement disorder symptoms
c) a database or other remote facility comprising at least one second processor in communication with the movement disorder monitoring device or an algorithm based on the database and adapted to receive the acquired movement data and/or quantified symptom severity from the movement disorder monitoring device;
d) the least one processor or the at least one second processor adapted to analyze the movement data and/or quantified symptom severity and to determine a quantified efficacy of the drug dose or drug pump or DBS therapy or treatment parameters at alleviating the subject's movement disorder symptoms and to determine whether the drug dose or drug pump or DBS device therapy or treatment parameters should be changed;
e) a system output comprising a new drug dose or new therapy or treatment parameters for the drug pump or DBS device based at least in part on the results of the analysis; and
f) at least one remote interface adapted for providing clinician or physician access to the movement data, quantified symptom severity, quantified efficacy, and/or system output and to allow the new drug dose or new therapy or treatment parameters to be entered into the drug pump or DBS device.